Search the webpage

Created by Giedrius Kalesnykas on   January 27, 2020   in category: News

Kuopio, Finland, 27th January 2019: Experimentica Ltd., a global ophthalmic contract research organization (CRO) today announced the appointment of Guillaume Demarne, Pharm.D. to Director of Business Development.

Dr. Demarne received his Pharm.D. from Aix-Marseille University, France. He holds an Advanced Master from EM Lyon Business School and was trained in entrepreneurship and intercultural management at East China Normal University, Shanghai.

Prior to joining Experimentica Ltd., Dr. Demarne held several pharmaceutical Business Development positions in France, the United States, and China. Most recently, he served for three years as Chief Business Development Officer at Balmes Transplantation SAS, an early stage pharmaceutical company focused on the prevention of organ ischemia-reperfusion injuries.

Dr. Giedrius Kalesnykas, President and CEO of Experimentica Ltd., commented: “Over the past five years, we have substantially grown our presence on North American and European markets. As we are focusing on our global presence as an established and trusted partner in preclinical ophthalmic drug discovery, we were looking for a candidate with a deep understanding of global business development, especially in Asia, and a strong background in the biotech industry.

We are delighted that Dr. Demarne decided to join our team and lead our business development globally. He is an outstanding appointment for Experimentica in times when we aim to strengthen our business development in Southern Europe and Asia.”

About Experimentica Ltd.
Experimentica Ltd. is a preclinical contract research organization (CRO) dedicated to develop and provide ocular disease models. Relying entirely on in-house expertise, Experimentica Ltd. pursues Scientific Excellence in Ocular Models.

Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland, Forest Park, IL, USA, Shanghai, China, and an R&D site in Vilnius, Lithuania. For more information, visit

Media enquiries:
Giedrius Kalesnykas, Ph.D.,
President and Chief Executive Officer
Phone: +358 (40) 930-7087
US Toll Free: +1 (844) 393-4393


Refinement of the EAE Mouse Model

Experimental Autoimmune Encephalomyelitis (EAE) is used to study Multiple Sclerosis (MS) a chronic neuroinflammatory demyelinating disorder of the CNS. EAE ... Read More

Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells

The cornea is critical for penetration of topically applied drugs into the eye. Assessment of the permeability properties of drug ... Read More

A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo

Keratoconjunctivitis sicca (KCS) is a multifactorial disease of the lacrimal glands and ocular surface1. Pathological findings in patients with KCS ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!